{"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Disease-free failure events include local progression, distant progression biochemical failure as defined by the Radiation Therapy Oncology Group (RTOG) Phoenix definition, and death from any cause. Participants will be considered to be without biochemical recurrence if either the PSA is still declining or the prostate-specific antigen (PSA) has not risen above its nadir by ≥ 2 ng/ml (Phoenix definition).","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.\n\nSBRT: 8.0Gy escalated dose\n\nRadiation Therapy Treatment Planning and Simulation: Undergo urethral-sparing IMRT planning\n\nSBRT: Undergo moderate dose SBRT with SIB","id":"OG000","title":"Arm A (Moderate Dose SBRT With SIB)"},{"description":"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.\n\nSBRT: 7.5Gy conventional dose\n\nRadiation Therapy Treatment Planning and Simulation: Undergo urethral-sparing IMRT planning\n\nSBRT: Undergo uniform dose SBRT","id":"OG001","title":"Arm B (Uniform Dose SBRT)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Disease-free Survival as Measured by the Phoenix Definition","type":"PRIMARY","unitOfMeasure":"months"}